About: COVID-19 Treatment: Close to a Cure? – A Rapid Review of Pharmacotherapies for the Novel Coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 Treatment: Close to a Cure? – A Rapid Review of Pharmacotherapies for the Novel Coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 Treatment: Close to a Cure? – A Rapid Review of Pharmacotherapies for the Novel Coronavirus
Creator	Song, Yang Zhou, Mi Wang, Kunkun Pharmd, Yiyi Pharmd, Yun Yin Pharmd, Ling Zhang Pharmd, Min
Source	Elsevier; Medline; PMC; WHO
abstract	Currently, there is no approved therapy for COVID-19. The World Health Organization therefore endorse supportive care only. However, frontline clinicians and researchers have been experimenting with several virus-based and host-based therapeutics since the outbreak in China. China's National Health Commission has issued the first COVID-19 Treatment Guideline with therapy suggestions (7(th) edition attached) which inspired following clinical studies worldwide. Major therapeutics are evaluated in this review. Key evidence from in vitro researches, animal models and clinical researches in emerging coronaviruses are examined. Antiviral therapies remdesivir, lopinavir/ritonavir and umifenovir, if considered, could be initiated before the peak of viral replication for optimal outcomes. Ribavirin may be beneficial as an add-on therapy and is ineffective as a monotherapy. Corticosteroids use should be limited to indicating comorbidities. IVIG is not recommended due to lack of data in COVID-19. Xuebijing may benefit patients with complications of bacterial pneumonia or sepsis. The efficacy of interferon is unclear due to conflicting outcomes in coronavirus studies. Chloroquine and hydroxychloroquine have shown in vitro inhibition of SARS-CoV-2, and the studies on clinical efficacy and whether the benefits outweigh the risk of dysrhythmias remain inconclusive. For patients who developed cytokine release syndrome, interleukin-6 inhibitors may be beneficial.
has issue date	2020-07-04(xsd:dateTime)
bibo:doi	10.1016/j.ijantimicag.2020.106080
bibo:pmid	32634603
has license	no-cc
sha1sum (hex)	e97b8899fc58988c79b73fc00cedf04cae23ef7b
schema:url	https://doi.org/10.1016/j.ijantimicag.2020.106080
resource representing a document's title	COVID-19 Treatment: Close to a Cure? – A Rapid Review of Pharmacotherapies for the Novel Coronavirus
has PubMed Central identifier	PMC7334905
has PubMed identifier	32634603
schema:publication	Int J Antimicrob Agents
resource representing a document's body	covid:e97b8899fc58988c79b73fc00cedf04cae23ef7b#body_text
is schema:about of	named entity 'INCONCLUSIVE' named entity 'MONOTHERAPY' named entity 'CYTOKINE RELEASE SYNDROME' named entity 'XUEBIJING' named entity 'SEPSIS' named entity 'dysrhythmias' named entity 'coronavirus' named entity 'National Health Commission' named entity 'COVID' named entity 'interleukin-6' named entity 'lopinavir/ritonavir' named entity 'outbreak in China' named entity 'clinical studies' named entity 'virus' named entity 'animal models' named entity 'hydroxychloroquine' named entity 'apoptosis' named entity 'viral replication' named entity 'immunoglobulins' named entity 'COVID' named entity 'polyprotein' named entity 'Chloroquine' named entity 'antiviral' named entity 'viral protein' named entity 'targeted therapy' named entity 'lopinavir/ritonavir' named entity 'IL-6' named entity 'CT scans' named entity 'ribavirin' named entity 'Wuhan' named entity 'anti-inflammatory' named entity 'IFN' named entity 'intestinal flora' named entity 'animal studies' named entity 'anti-inflammatory' named entity 'corticosteroid' named entity 'non-infectious' named entity 'interferon β' named entity 'COVID' named entity 'control group' named entity 'nausea' named entity 'abdominal pain' named entity 'infection' named entity 'multicentric Castleman disease' named entity 'mood swing' named entity 'APACHE II' named entity 'IVIG' named entity 'thrombocytopenia' named entity 'infection' named entity 'PubMed' named entity 'lung' named entity 'LPV' named entity 'IL-6' named entity 'diarrhea' named entity 'viral titers' named entity 'corticosteroids' named entity 'steroid' named entity '19 management' named entity 'community-acquired pneumonia' named entity 'not-for-profit' named entity 'Physiology' named entity 'cytopenia' named entity 'single-blind' named entity 'rheumatoid arthritis' named entity 'hypotension' named entity 'remdesivir' named entity 'COVID' named entity 'remdesivir' named entity 'ICU' named entity 'lung' named entity 'critically ill patients' named entity 'interleukin-6' named entity 'IVIG' named entity 'ACTT' named entity 'Ribavirin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software